Yahoo Finance • last year
The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the last three years have been particularly tough on longer term MeiraGTx Holdings plc (NASDAQ:MGTX) shareholders. Unfortunately, they hav... Full story
Yahoo Finance • last year
LONDON and NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Office... Full story
Yahoo Finance • last year
MeiraGTx Holdings PLC (NASDAQ:MGTX) announces Q3 2023 financial results with a net loss of $44.3 million. Sanofi's strategic investment of $30 million in MGTX shares and a right of first negotiation for gene regulation technology. Company'... Full story
Yahoo Finance • last year
- Received strategic investment from Sanofi purchasing $30 million of ordinary shares of the Company at a price of $7.50 per share in October 2023 - Announced a right of first negotiation (ROFN) with Sanofi for the use of MeiraGTx’s Ribos... Full story
Yahoo Finance • last year
Sanofi to purchase $30 million of ordinary shares of the Company at a price of $7.50 per share Sanofi to receive a right of first negotiation (ROFN) for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology an... Full story
Yahoo Finance • last year
LONDON and NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit eight posters and deliver one oral presen... Full story
Yahoo Finance • last year
Clinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 monthsIncreases in whole saliva flow rates observed post-treatm... Full story
Yahoo Finance • 2 years ago
LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on... Full story
Yahoo Finance • 2 years ago
LONDON and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit nine poster presentations at the American... Full story
Yahoo Finance • 2 years ago
Raised approximately $60 million in a private placement in May 2023 with investors consisting of several of the Company’s top shareholders On track for BLA submission of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the trea... Full story
Yahoo Finance • 2 years ago
LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 10.7 million ordinary shar... Full story
Yahoo Finance • 2 years ago
Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2 signaling pathway to accelerate a series of cli... Full story
Yahoo Finance • 2 years ago
- Announced positive clinical data from AQUAx AAV-hAQP1 Phase 1 trial for treatment of Grade 2/3Radiation-Induced Xerostomia in December 2022 - Announced positive top-line data from the MGT009 Phase 1/2 clinical study demonstrating sa... Full story
Yahoo Finance • 2 years ago
-- Updated Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) --Now Dosing Patients in Phase 1 Trial Evaluating AAV-GAD Gene Therapy for Parkin... Full story
Yahoo Finance • 2 years ago
-- Recent Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Financing Secured by Manufacturing Facilities Extends Cash Runway to Fourth Qua... Full story
Yahoo Finance • 2 years ago
- Credit facility is collateralized by MeiraGTx’s wholly-owned manufacturing facilities in London, UK and Shannon, Ireland - $75 million at closing strengthens balance sheet and extends runway to fourth quarter of 2024 LONDON and NEW YOR... Full story
Yahoo Finance • 2 years ago
• The primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated • Significant improvements were demonstrated in multiple different endpoints in botaretigene s... Full story
Yahoo Finance • 3 years ago
- Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing Patients - Phase 1 AQUAx Study of AAV-hAQP1 for Radiation-Induced Xerostomia Completed Dosin... Full story
Yahoo Finance • 3 years ago
LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu... Full story
Yahoo Finance • 3 years ago
LONDON and NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Offic... Full story